Alan D Michelson

Summary

Affiliation: University of Massachusetts Medical School
Country: USA

Publications

  1. ncbi Platelet and platelet-derived microparticle surface factor V/Va binding in whole blood: differences between neonates and adults
    A D Michelson
    Center for Platelet Function Studies, Department of Pediatrics, University of Massachusetts Medical School, Worcester 01655, USA
    Thromb Haemost 84:689-94. 2000
  2. ncbi Pharmacodynamic assessment of platelet inhibition by prasugrel vs. clopidogrel in the TRITON-TIMI 38 trial
    Alan D Michelson
    Department of Medicine, Children s Hospital Boston, Center for Platelet Research Studies, Division of Hematology Oncology, Boston, MA 02115, USA
    Eur Heart J 30:1753-63. 2009
  3. ncbi Platelet inhibitor therapy: mechanisms of action and clinical use
    Alan D Michelson
    Center for Platelet Function Studies, Department of Pediatrics, University of Massachusetts Medical School, Worcester, MA 01655, USA
    J Thromb Thrombolysis 16:13-5. 2003
  4. ncbi P2Y12 antagonism: promises and challenges
    Alan D Michelson
    Center for Platelet Function Studies, University of Massachusetts Medical School, Room S5 846, 55 Lake Avenue North, Worcester, MA 01655, USA
    Arterioscler Thromb Vasc Biol 28:s33-8. 2008
  5. ncbi Current options in platelet function testing
    Alan D Michelson
    Center for Platelet Function Studies, Division of Cardiovascular Medicine, Department of Pediatrics and Department of Medicine, University of Massachusetts Medical School, Worcester, Massachusetts 01655, USA
    Am J Cardiol 98:4N-10N. 2006
  6. ncbi Platelet function testing in cardiovascular diseases
    Alan D Michelson
    Center for Platelet Function Studies, Department of Pediatrics, University of Massachusetts Medical School, Worcester, Mass 01655, USA
    Circulation 110:e489-93. 2004
  7. ncbi Flow cytometric analysis of platelets
    A D Michelson
    Center for Platelet Function Studies, University of Massachusetts Medical School, Worcester, USA
    Vox Sang 78:137-42. 2000
  8. ncbi Evidence that pre-existent variability in platelet response to ADP accounts for 'clopidogrel resistance'
    A D Michelson
    Center for Platelet Function Studies, University of Massachusetts Medical School, Worcester, MA 01655, USA
    J Thromb Haemost 5:75-81. 2007
  9. ncbi Laboratory markers of platelet activation and their clinical significance
    A D Michelson
    Center for Platelet Function Studies, Department of Pediatrics, University of Massachusetts Medical School, Worcester 01655, USA
    Curr Opin Hematol 6:342-8. 1999
  10. ncbi Aspirin resistance: position paper of the Working Group on Aspirin Resistance
    A D Michelson
    Department of Pediatrics, Center for Platelet Function Studies, University of Massachusetts Medical School, Worcester, MA 01655, USA
    J Thromb Haemost 3:1309-11. 2005

Detail Information

Publications95

  1. ncbi Platelet and platelet-derived microparticle surface factor V/Va binding in whole blood: differences between neonates and adults
    A D Michelson
    Center for Platelet Function Studies, Department of Pediatrics, University of Massachusetts Medical School, Worcester 01655, USA
    Thromb Haemost 84:689-94. 2000
    ..4) The percent PDMP does not necessarily reflect the degree of procoagulant activity of PDMP or platelets...
  2. ncbi Pharmacodynamic assessment of platelet inhibition by prasugrel vs. clopidogrel in the TRITON-TIMI 38 trial
    Alan D Michelson
    Department of Medicine, Children s Hospital Boston, Center for Platelet Research Studies, Division of Hematology Oncology, Boston, MA 02115, USA
    Eur Heart J 30:1753-63. 2009
    ..To examine the extent of platelet inhibition by prasugrel vs. clopidogrel in a TRITON-TIMI 38 substudy...
  3. ncbi Platelet inhibitor therapy: mechanisms of action and clinical use
    Alan D Michelson
    Center for Platelet Function Studies, Department of Pediatrics, University of Massachusetts Medical School, Worcester, MA 01655, USA
    J Thromb Thrombolysis 16:13-5. 2003
    ..This article briefly reviews the mechanisms of action and clinical uses of platelet inhibitor therapy...
  4. ncbi P2Y12 antagonism: promises and challenges
    Alan D Michelson
    Center for Platelet Function Studies, University of Massachusetts Medical School, Room S5 846, 55 Lake Avenue North, Worcester, MA 01655, USA
    Arterioscler Thromb Vasc Biol 28:s33-8. 2008
    ..Whether this promise will be translated into clinical benefit for patients will be determined by the results of ongoing phase 3 clinical trials...
  5. ncbi Current options in platelet function testing
    Alan D Michelson
    Center for Platelet Function Studies, Division of Cardiovascular Medicine, Department of Pediatrics and Department of Medicine, University of Massachusetts Medical School, Worcester, Massachusetts 01655, USA
    Am J Cardiol 98:4N-10N. 2006
    ..In patients treated with antiplatelet drugs, the degree of platelet inhibition, as determined by several of these new platelet function assays, has been shown to predict major adverse cardiac events...
  6. ncbi Platelet function testing in cardiovascular diseases
    Alan D Michelson
    Center for Platelet Function Studies, Department of Pediatrics, University of Massachusetts Medical School, Worcester, Mass 01655, USA
    Circulation 110:e489-93. 2004
  7. ncbi Flow cytometric analysis of platelets
    A D Michelson
    Center for Platelet Function Studies, University of Massachusetts Medical School, Worcester, USA
    Vox Sang 78:137-42. 2000
    ..Despite recent progress in our understanding of platelet function in vitro, there remains a remarkable paucity of methods to study platelet function in vivo...
  8. ncbi Evidence that pre-existent variability in platelet response to ADP accounts for 'clopidogrel resistance'
    A D Michelson
    Center for Platelet Function Studies, University of Massachusetts Medical School, Worcester, MA 01655, USA
    J Thromb Haemost 5:75-81. 2007
    ..Clopidogrel is a widely used antithrombotic agent that inhibits the platelet P2Y(12) adenosine diphosphate (ADP) receptor. There is increasing interest in 'clopidogrel resistance'...
  9. ncbi Laboratory markers of platelet activation and their clinical significance
    A D Michelson
    Center for Platelet Function Studies, Department of Pediatrics, University of Massachusetts Medical School, Worcester 01655, USA
    Curr Opin Hematol 6:342-8. 1999
    ....
  10. ncbi Aspirin resistance: position paper of the Working Group on Aspirin Resistance
    A D Michelson
    Department of Pediatrics, Center for Platelet Function Studies, University of Massachusetts Medical School, Worcester, MA 01655, USA
    J Thromb Haemost 3:1309-11. 2005
  11. ncbi Evaluation of platelet function by flow cytometry
    Alan D Michelson
    Department of Pediatrics, Center for Platelet Function Studies, University of Massachusetts Medical School, Worcester, 01655, USA
    Pathophysiol Haemost Thromb 35:67-82. 2006
  12. ncbi Aspirin resistance
    Alan D Michelson
    Department of Pediatrics, Center for Platelet Function Studies, University of Massachusetts Medical School, Worcester, 01655, USA
    Pathophysiol Haemost Thromb 35:5-9. 2006
  13. ncbi Platelet function testing in cardiovascular diseases
    Alan D Michelson
    Center for Platelet Function Studies, Departments of Pediatrics, Medicine, and Pathology, University of Massachusetts Medical School, Worcester, MA 01655, USA
    Hematology 10:132-7. 2005
  14. ncbi Circulating monocyte-platelet aggregates are a more sensitive marker of in vivo platelet activation than platelet surface P-selectin: studies in baboons, human coronary intervention, and human acute myocardial infarction
    A D Michelson
    Center for Platelet Function Studies, Departments of Pediatrics and Medicine, University of Massachusetts Medical School, Worcester, MA 01655, USA
    Circulation 104:1533-7. 2001
    ..Platelet surface P-selectin is considered the "gold standard" marker of platelet activation. Degranulated, P-selectin-positive platelets, however, aggregate with leukocytes in vitro and rapidly lose surface P-selectin in vivo...
  15. ncbi How platelets work: platelet function and dysfunction
    Alan D Michelson
    Center for Platelet Function Studies, Department of Pediatrics, University of Massachusetts Medical School, Worcester, MA 01655, USA
    J Thromb Thrombolysis 16:7-12. 2003
    ..This article briefly reviews (a) how platelets normally function and (b) the clinical approach to disorders of platelet numbers and function...
  16. ncbi Antiplatelet strategies: evaluating their current role in the setting of acute coronary syndromes
    Eugene Braunwald
    TIMI Study Group, Cardiovascular Division, Brigham and Women s Hospital, Department of Medicine, Harvard Medical School, 350 Longwood Avenue, Boston, Massachusetts 02115, USA
    Clin Cardiol 31:I2-9. 2008
    ..Currently, it appears that the use of GP IIb/IIIa antagonists might be most beneficial in high-risk ACS patients scheduled to undergo PCI, who demonstrate non-ST-segment elevation myocardial infarction and elevated troponin levels...
  17. ncbi Investigating the mechanisms of hyporesponse to antiplatelet approaches
    Eugene Braunwald
    TIMI Study Group, Cardiovascular Division, Brigham and Women s Hospital, Department of Medicine, Harvard Medical School, 350 Longwood Avenue, Boston, Massachusetts 02115, USA
    Clin Cardiol 31:I21-7. 2008
    ..Results from these studies could cause a paradigm shift toward individualized antiplatelet therapy, improving predictability of platelet inhibition, and diminishing the likelihood for hyporesponsiveness...
  18. ncbi Residual arachidonic acid-induced platelet activation via an adenosine diphosphate-dependent but cyclooxygenase-1- and cyclooxygenase-2-independent pathway: a 700-patient study of aspirin resistance
    Andrew L Frelinger
    Center for Platelet Function Studies, Department of Pediatrics, UMass Memorial Medical Center, 55 Lake Ave N, Worcester, Massachusetts 01655, USA
    Circulation 113:2888-96. 2006
    ....
  19. ncbi Clinical considerations with the use of antiplatelet therapy in patients undergoing percutaneous coronary intervention
    Eugene Braunwald
    TIMI Study Group, Cardiovascular Division, Brigham and Women s Hospital, Department of Medicine, Harvard Medical School, 350 Longwood Avenue, Boston, Massachusetts 02115, USA
    Clin Cardiol 31:I28-35. 2008
    ..Patient nonadherence to treatment and premature discontinuation and underutilization of antiplatelet therapies by physicians remain important clinical problems with potentially dire consequences...
  20. ncbi The active metabolite of prasugrel inhibits ADP-stimulated thrombo-inflammatory markers of platelet activation: Influence of other blood cells, calcium, and aspirin
    Andrew L Frelinger
    Center for Platelet Function Studies, University of Massachusetts Medical School, 55 Lake Avenue North, Worcester, MA 01655, USA
    Thromb Haemost 98:192-200. 2007
    ..This inhibition is enhanced in the presence other blood cells and calcium, but not aspirin...
  21. ncbi The problem of persistent platelet activation in acute coronary syndromes and following percutaneous coronary intervention
    Eugene Braunwald
    TIMI Study Group, Cardiovascular Division, Brigham and Women s Hospital, Department of Medicine, Harvard Medical School, 350 Longwood Avenue, Boston, Massachusetts 02115, USA
    Clin Cardiol 31:I17-20. 2008
    ..Aspirin, thienopyridines, and glycoprotein IIb/IIIa inhibitors, the 3 major pharmacologic approaches to persistent platelet activation, target various levels of the hemostatic pathways and thrombus formation...
  22. ncbi Association of cyclooxygenase-1-dependent and -independent platelet function assays with adverse clinical outcomes in aspirin-treated patients presenting for cardiac catheterization
    Andrew L Frelinger
    Division of Hematology Oncology, Children s Hospital Boston, 300 Longwood Ave, Boston, MA 02115 5737, USA
    Circulation 120:2586-96. 2009
    ..The objectives of this study were to determine prospectively whether COX-1-dependent and other platelet function assays correlate with clinical outcomes in aspirin-treated patients...
  23. ncbi Intrinsic platelet reactivity before P2Y12 blockade contributes to residual platelet reactivity despite high-level P2Y12 blockade by prasugrel or high-dose clopidogrel. Results from PRINCIPLE-TIMI 44
    Andrew L Frelinger
    Center for Platelet Research Studies, Division of Hematology Oncology, Children s Hospital Boston, Dana Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts, USA
    Thromb Haemost 106:219-26. 2011
    ..Patients who are hyper-responsive to ADP pre-treatment are more likely to be hyper-responsive to ADP on-treatment, which may be relevant to therapeutic strategies...
  24. ncbi Pharmacodynamic effect and clinical efficacy of clopidogrel and prasugrel with or without a proton-pump inhibitor: an analysis of two randomised trials
    Michelle L O'Donoghue
    TIMI Study Group, Brigham and Women s Hospital, Boston, MA 02115, USA
    Lancet 374:989-97. 2009
    ..Conflicting data exist as to whether PPIs diminish the efficacy of clopidogrel. We assessed the association between PPI use, measures of platelet function, and clinical outcomes for patients treated with clopidogrel or prasugrel...
  25. ncbi Application of flow cytometry to platelet disorders
    Matthew D Linden
    Center for Platelet Function Studies, University of Massachusetts Medical School, Worcester, MA 01655, USA
    Semin Thromb Hemost 30:501-11. 2004
    ..Accordingly, this review summarizes the key technical and methodologic components of flow cytometric analysis of platelets, as well as specific examples of its application to diagnosis and patient care...
  26. ncbi Whole blood analysis of leukocyte-platelet aggregates
    Marc R Barnard
    University of Massachusetts Medical School, Worcester, Massachusetts, USA
    Curr Protoc Cytom . 2003
    ..Light scatter and at least one leukocyte-specific antibody are used to gate the desired population, and the presence of associated platelets is detected by immunostaining for abundant platelet-specific markers...
  27. ncbi Prasugrel compared with high loading- and maintenance-dose clopidogrel in patients with planned percutaneous coronary intervention: the Prasugrel in Comparison to Clopidogrel for Inhibition of Platelet Activation and Aggregation-Thrombolysis in Myocardial
    Stephen D Wiviott
    Brigham and Women s Hospital, Cardiovascular Division, 75 Francis St, Boston, MA 02115, USA
    Circulation 116:2923-32. 2007
    ..The relative antiplatelet effects of prasugrel versus high-dose clopidogrel in percutaneous coronary intervention patients are unknown...
  28. ncbi Release of soluble CD40L from platelets is regulated by glycoprotein IIb/IIIa and actin polymerization
    Mark I Furman
    Center for Platelet Function Studies, University of Massachusetts Medical School, Worcester, Massachusetts 01655, USA
    J Am Coll Cardiol 43:2319-25. 2004
    ..In addition to their well-characterized inhibition of platelet aggregation, GP IIb/IIIa antagonists may obviate the proinflammatory and prothrombotic effects of sCD40L...
  29. ncbi Platelet activation in cystic fibrosis
    Brian P O'Sullivan
    Department of Pediatrics, UMass Memorial Health Care and University of Massachusetts Medical School, Worcester, MA 01655, USA
    Blood 105:4635-41. 2005
    ..Our findings may account, at least in part, for the beneficial effects of ibuprofen in CF...
  30. ncbi Effects of platelet binding on whole blood flow cytometry assays of monocyte and neutrophil procoagulant activity
    M R Barnard
    Center for Platelet Function Studies, University of Massachusettes Medical School, Worcester, MA 01655, USA
    J Thromb Haemost 3:2563-70. 2005
    ....
  31. ncbi The Platelet Activity After Clopidogrel Termination (PACT) study
    Andrew L Frelinger
    Center for Platelet Research Studies, Division of Hematology Oncology, Children s Hospital Boston, Harvard Medical School, Boston, MA 02115 5737, USA
    Circ Cardiovasc Interv 3:442-9. 2010
    ..We therefore performed a randomized, double-blind, placebo-controlled, crossover study: the Platelet Activity after Clopidogrel Termination (PACT) study...
  32. ncbi Assessing the current role of platelet function testing
    Eugene Braunwald
    TIMI Study Group, Cardiovascular Division, Brigham and Women s Hospital, Department of Medicine, Harvard Medical School, 350 Longwood Avenue, Boston, Massachusetts 02115, USA
    Clin Cardiol 31:I10-6. 2008
    ..The ideal platelet function test for clinical practice would be rapid, easy-to-use, inexpensive, and reliable...
  33. ncbi Dosing clopidogrel based on CYP2C19 genotype and the effect on platelet reactivity in patients with stable cardiovascular disease
    Jessica L Mega
    TIMI Study Group, Cardiovascular Division, Department of Medicine, Brigham and Women s Hospital, 75 Francis St, Boston, MA 02115, USA
    JAMA 306:2221-8. 2011
    ..Variants in the CYP2C19 gene influence the pharmacologic and clinical response to the standard 75-mg daily maintenance dose of the antiplatelet drug clopidogrel...
  34. ncbi Immunophenotypic analysis of platelets
    Lori A Krueger
    University of Massachusetts Medical School, Worcester, Massachusetts, USA
    Curr Protoc Cytom . 2002
    ..Detailed discussion of appropriate sample handling, reagent preparation, flow cytometric set-up, and data interpretation are provided for three independent assays...
  35. ncbi Combined effects of mild hypothermia and glycoprotein IIb/IIIa antagonists on platelet-platelet and leukocyte-platelet aggregation
    Andrew L Frelinger
    Center for Platelet Function Studies, Department of Pediatrics, University of Massachusetts Medical School, Worcester 01655, USA
    Am J Cardiol 92:1099-101. 2003
    ....
  36. ncbi Effect of adenosine A2 receptor stimulation on platelet activation-aggregation: differences between canine and human models
    Matthew D Linden
    Center for Platelet Function Studies, University of Massachusetts Medical School, Worcester MA 01655, United States
    Thromb Res 121:689-98. 2008
    ....
  37. ncbi Quantification of abciximab-induced platelet inhibition is assay dependent: a comparative study in patients undergoing percutaneous coronary intervention
    Mark I Furman
    Center for Platelet Function Studies and Division of Cardiovascular Medicine, Department of Medicine, University of Massachusetts Medical School, Worcester, MA 01655, USA
    Am Heart J 145:e6. 2003
    ....
  38. ncbi Serial determinations of platelet counts in mice by flow cytometry
    K R Alugupalli
    Department of Molecular Genetics and Microbiology, University of Massachusetts Medical School, Worcester 01655, USA
    Thromb Haemost 86:668-71. 2001
    ..Therefore, this method can be used to follow the number and the activation state of circulating platelets from individual mice over extended periods of time and is applicable to a wide range of murine models of platelet disorders...
  39. ncbi Increased platelet reactivity and circulating monocyte-platelet aggregates in patients with stable coronary artery disease
    M I Furman
    Cardiovascular Thrombosis Research Center, Department of Medicine, University of Massachusetts Medical Center, Worcester 01655, USA
    J Am Coll Cardiol 31:352-8. 1998
    ..We sought to examine whether patients with stable coronary artery disease (CAD) have increased platelet reactivity and an enhanced propensity to form monocyte-platelet aggregates...
  40. ncbi The platelet hyporeactivity of extremely low birth weight neonates is age-dependent
    Francis J Bednarek
    Neonatology, Department of Pediatrics, University of Massachusetts Medical School and UMass Memorial Health Care, Worcester, MA 01655, USA
    Thromb Res 124:42-5. 2009
    ..The purpose of this study was to examine the age dependency of this hyporeactivity...
  41. ncbi Evaluation of platelet function by flow cytometry
    A D Michelson
    Center for Platelet Function Studies, University of Massachusetts Medical School, Worcester, Massachusetts, 01655, USA
    Methods 21:259-70. 2000
    ....
  42. ncbi GPIIb-IIIa antagonists reduce thromboinflammatory processes in patients with acute coronary syndromes undergoing percutaneous coronary intervention
    M I Furman
    Cardiac Catheterization Laboratories, UMass Memorial Medical Center, University of Massachusetts Medical School, Worcester, MA 01605, USA
    J Thromb Haemost 3:312-20. 2005
    ....
  43. ncbi High-dose heparin suppresses platelet alpha granule secretion
    M J Rohrer
    Division of Vascular Surgery, University of Massachusetts Medical School, Worcester 01655
    J Vasc Surg 15:1000-8; discussion 1008-9. 1992
    ....
  44. ncbi A randomized, 2-period, crossover design study to assess the effects of dexlansoprazole, lansoprazole, esomeprazole, and omeprazole on the steady-state pharmacokinetics and pharmacodynamics of clopidogrel in healthy volunteers
    Andrew L Frelinger
    Center for Platelet Research Studies, Division of Hematology Oncology, Children s Hospital Boston, Dana Farber Cancer Institute, Harvard Medical School, Boston, MA 02115, USA
    J Am Coll Cardiol 59:1304-11. 2012
    ..The aim of this study was to assess the effects of different proton pump inhibitors (PPIs) on the steady-state pharmacokinetics and pharmacodynamics of clopidogrel...
  45. ncbi The influence of intermittent hypoxemia on platelet activation in obese patients with obstructive sleep apnea
    Shilpa Rahangdale
    Division of Sleep Medicine, Brigham and Women s Hospital and Harvard Medical School, Boston, MA, USA
    J Clin Sleep Med 7:172-8. 2011
    ..Given the central role of platelets in atherothrombosis and the known cardiovascular risk of OSA, we hypothesized that OSA severity is predictive of platelet function, independent of known comorbidities...
  46. ncbi Indices of platelet activation and the stability of coronary artery disease
    M D Linden
    Center for Platelet Function Studies, University of Massachusetts Medical School, Worcester, MA 01655, USA
    J Thromb Haemost 5:761-5. 2007
    ..To determine whether indices of platelet activation are associated with the stability of coronary artery disease (CAD)...
  47. ncbi In vitro testing of fresh and lyophilized reconstituted human and baboon platelets
    C R Valeri
    Naval Blood Research Laboratory, Boston University School of Medicine, Boston, Massachusetts 02118, USA
    Transfusion 44:1505-12. 2004
    ..Lyophilization has been developed as a method to preserve PLTs. This study was performed to evaluate these measurements on human and baboon fresh and lyophilized reconstituted PLTs...
  48. ncbi Platelet hyporeactivity in very low birth weight neonates
    D Rajasekhar
    Department of Pediatrics, University of Massachusetts Medical School, Worcester, USA
    Thromb Haemost 77:1002-7. 1997
    ..In addition to its previously defined use as a test of platelet hyperreactivity, the present study suggests that whole blood flow cytometry may be useful in the clinical assessment of platelet hyporeactivity...
  49. ncbi Agonist and antagonist effects of diadenosine tetraphosphate, a platelet dense granule constituent, on platelet P2Y1, P2Y12 and P2X1 receptors
    Hung Chang
    Center for Platelet Function Studies, Department of Pediatrics, University of Massachusetts Medical School, Worcester, MA, USA
    Thromb Res 125:159-65. 2010
    ..Diadenosine 5',5'''-P(1),P(4)- tetraphosphate (Ap(4)A) is stored in platelet dense granules, but its effects on platelet function are not well understood...
  50. ncbi Methods for the measurement of platelet function
    Alan D Michelson
    Center for Platelet Function Studies, University of Massachusetts Medical School, Worcester, Massachusetts, USA
    Am J Cardiol 103:20A-26A. 2009
    ..Some of the factors that differentiate these tests are sample volume requirements, the use of whole blood, the presence of shear, point-of-care status, need for a technician, and expense...
  51. ncbi Antiplatelet therapies for the treatment of cardiovascular disease
    Alan D Michelson
    Center for Platelet Research Studies, Children s Hospital Boston, Karp 08213, 300 Longwood Avenue, Boston, Massachusetts 02115 5737, USA
    Nat Rev Drug Discov 9:154-69. 2010
    ..This article reviews the role of platelets in haemostasis and cardiovascular thrombosis, and discusses the benefits and limitations of current and investigational antiplatelet agents in the treatment of cardiovascular disease...
  52. ncbi Survival of baboon biotin-X-N-hydroxysuccinimide and (111)In-oxine-labelled autologous fresh and lyophilized reconstituted platelets
    C R Valeri
    Naval Blood Research Laboratory, Boston University School of Medicine, Boston, MA, USA
    Vox Sang 88:122-9. 2005
    ..Studies are being conducted to determine the effects of lyophilization of platelets. In the present study, we assessed the survival of autologous lyophilized-reconstituted platelets in the baboon...
  53. ncbi Preconditioning ischemia attenuates molecular indices of platelet activation-aggregation
    M D Linden
    Center for Platelet Function Studies, University of Massachusetts Medical School, Worcester, MA 01655, USA
    J Thromb Haemost 4:2670-7. 2006
    ..190% +/- 21% of baseline; *P < 0.05 and P = 0.09 vs. control). CONCLUSION: These data provide novel, direct evidence in support of the concept that ischemic PC attenuates molecular indices of platelet activation-aggregation...
  54. ncbi Circulating monocyte-platelet aggregates are an early marker of acute myocardial infarction
    M I Furman
    Center for Platelet Function Studies, Division of Cardiovascular Medicine, Worcester, Massachusetts 01655, USA
    J Am Coll Cardiol 38:1002-6. 2001
    ..We investigated whether elevated levels of circulating monocyte-platelet aggregates (MPA) can be used to identify patients with acute myocardial infarction (AMI)...
  55. ncbi Platelet FcgammaRIIA His131Arg polymorphism and platelet function: antibodies to platelet-bound fibrinogen induce platelet activation
    J Chen
    Department of Medicine, Baylor College of Medicine, Houston, Texas, USA
    J Thromb Haemost 1:355-62. 2003
    ....
  56. ncbi Laser scanning cytometry: a novel method for the detection of platelet--endothelial cell adhesion
    R B Claytor
    Department of Surgery, Division of Vascular Surgery, University of Massachusetts Medical School, Worcester, Massachusetts 01655, USA
    Cytometry 43:308-13. 2001
    ..We report a novel method for in vitro detection of platelet-endothelial cell adhesion that allows endothelial cells to remain as an intact monolayer and for visualization of individual platelets...
  57. ncbi Platelet activation results in a redistribution of glycoprotein IV (CD36)
    A D Michelson
    Department of Pediatrics, University of Massachusetts Medical School, Worcester 01655
    Arterioscler Thromb 14:1193-201. 1994
    ..In summary, both in vitro and in vivo platelet activation results in increased platelet surface expression of GPIV, as a result of a redistribution of GPIV from an internal pool...
  58. ncbi New P2Y12 antagonists
    Alan D Michelson
    Center for Platelet Research Studies, Children s Hospital Boston, Brigham and Women s Hospital, Harvard Medical School, Boston, MA 02115 5737, USA
    Curr Opin Hematol 16:371-7. 2009
    ..However, clopidogrel has a number of disadvantages that have led to the development of new P2Y12 antagonists. This article reviews the current status of clopidogrel and these new P2Y12 antagonists...
  59. ncbi Platelet reactivity and the identification of acute coronary syndromes in the emergency department
    Chad E Darling
    Department of Emergency Medicine, University of Massachusetts Medical School, Worcester, MA 01655, USA
    J Thromb Thrombolysis 28:31-7. 2009
    ..This review will focus on selected tests/markers of platelet function that have shown some promise with respect to the risk stratification of patients with potential ACS...
  60. ncbi Therapeutic goals for effective platelet inhibition: a consensus document
    Stephen D Wiviott
    Cardiovascular Division, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA
    Rev Cardiovasc Med 7:214-25. 2006
    ..These novel agents such as prasugrel, AZD6140, and cangrelor are in advanced stages of clinical development for potential use in patients with coronary artery disease...
  61. ncbi The inflammatory role of platelets in cystic fibrosis
    Brian P O'Sullivan
    Department of Pediatrics, UMass Memorial Health Care, 55 Lake Avenue, North Worcester, MA 01655, USA
    Am J Respir Crit Care Med 173:483-90. 2006
    ..We hypothesize that platelet activation is important in CF lung disease and suggest research avenues that might help elucidate the role of activated platelets in CF...
  62. ncbi GPIIb/IIIa inhibitor-induced dethrombosis
    Mark I Furman
    Center for Platelet Function Studies, Division of Cardiovascular Medicine, University of Massachusetts Medical School, 55 Lake Avenue North, Worcester, MA 01655, USA
    J Thromb Thrombolysis 18:11-7. 2004
    ....
  63. ncbi GPIIb-IIIa antagonist-induced reduction in platelet surface factor V/Va binding and phosphatidylserine expression in whole blood
    M I Furman
    Center for Platelet Function Studies, University of Massachusetts Medical School, Worcester, PA 01655, USA
    Thromb Haemost 84:492-8. 2000
    ..Fibrinogen binding to GPIIb-IIIa is important in the generation of platelet procoagulant activity...
  64. ncbi Leukocyte-platelet aggregation, platelet surface P-selectin, and platelet surface glycoprotein IIIa after percutaneous coronary intervention: Effects of dalteparin or unfractionated heparin in combination with abciximab
    M I Furman
    Center for Platelet Function Studies and the Division of Cardiovascular Medicine, Departments of Medicine, Pediatrics, and Cell Biology, University of Massachusetts Medical School, Worcester, MA 01655, USA
    Am Heart J 142:790-8. 2001
    ..Low-molecular-weight heparins have been reported to cause less platelet activation than unfractionated heparin...
  65. ncbi Dissociation of glycoprotein IIb/IIIa antagonists from platelets does not result in fibrinogen binding or platelet aggregation
    A L Frelinger
    Center for Platelet Function Studies, University of Massachusetts Medical School, Worcester, MA 01655, USA
    Circulation 104:1374-9. 2001
    ..These apparently paradoxical results have been extensively referenced in the cardiology literature...
  66. ncbi Targeted inhibition of the serotonin 5HT2A receptor improves coronary patency in an in vivo model of recurrent thrombosis
    K Przyklenk
    Center for Platelet Function Studies, Department of Emergency Medicine, University of Massachusetts Medical School, Worcester, MA, USA
    J Thromb Haemost 8:331-40. 2010
    ..However, earlier-generation serotonin receptor antagonists were not successfully exploited as antiplatelet agents, possibly owing to their lack of specificity for the 5HT2A receptor subtype...
  67. ncbi The active metabolite of prasugrel inhibits adenosine diphosphate- and collagen-stimulated platelet procoagulant activities
    A L Frelinger
    Center for Platelet Function Studies, and Department of Pediatrics, University of Massachusetts Medical School, Worcester, MA 01655, USA
    J Thromb Haemost 6:359-65. 2008
    ..We therefore examined whether R-138727 inhibits ADP- and collagen-triggered platelet procoagulant activities...
  68. ncbi Antithrombotic therapy in the cardiac catheterization laboratory: focus on antiplatelet agents
    M I Furman
    Division of Cardiovascular Medicine, University of Massachusetts Medical School, 55 Lake Avenue North, Worcester, MA 01655, USA
    Curr Cardiol Rep 2:386-94. 2000
    ..Despite the growing use of GP IIb/IIIa antagonists, much information remains unknown as to the proper dosing and the effects these agents have on other elements of the hemostatic and vascular systems...
  69. ncbi Granule exocytosis is required for platelet spreading: differential sorting of α-granules expressing VAMP-7
    Christian G Peters
    Division of Hemostasis and Thrombosis, Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, USA
    Blood 120:199-206. 2012
    ....
  70. ncbi Spirochete-platelet attachment and thrombocytopenia in murine relapsing fever borreliosis
    Kishore R Alugupalli
    Department of Molecular Genetics and Microbiology, University of Massachusetts Medical School, 55 Lake Ave N, Worcester, MA 01655, USA
    Blood 102:2843-50. 2003
    ..These findings suggest that thrombocytopenia of relapsing fever is the result of platelet clearance after beta 3-independent bacterial attachment to circulating platelets...
  71. ncbi Dosing of clopidogrel for platelet inhibition in infants and young children: primary results of the Platelet Inhibition in Children On cLOpidogrel (PICOLO) trial
    Jennifer S Li
    Division of Pediatric Cardiology, Department of Pediatrics, Duke University Medical Center and Duke Clinical Research Institute, Durham, NC 27705, USA
    Circulation 117:553-9. 2008
    ....
  72. ncbi Neutrophil cathepsin G modulates the platelet surface expression of the glycoprotein (GP) Ib-IX complex by proteolysis of the von Willebrand factor binding site on GPIb alpha and by a cytoskeletal-mediated redistribution of the remainder of the complex
    C A LaRosa
    Division of Vascular Surgery, University of Massachusetts Medical School, Worcester 01655
    Blood 84:158-68. 1994
    ..abstract truncated at 400 words)..
  73. ncbi Aspirin 'resistance': role of pre-existent platelet reactivity and correlation between tests
    A L Frelinger
    Department of Pediatrics, Center for Platelet Function Studies, University of Massachusetts Medical School, Worcester, MA 01655, USA
    J Thromb Haemost 6:2035-44. 2008
    ..Aspirin 'resistance' is a widely used term for hyporesponsiveness to aspirin in a platelet function test. Serum thromboxane (TX) B(2) is the most specific test of aspirin's effect on platelets...
  74. ncbi Platelet activation by a relapsing fever spirochaete results in enhanced bacterium-platelet interaction via integrin alphaIIbbeta3 activation
    K R Alugupalli
    Department of Molecular Genetics and Microbiology, University of Massachusetts Medical School, 55 Lake Avenue North, Worcester, MA 01655, USA
    Mol Microbiol 39:330-40. 2001
    ..Thus, B. hermsii signals the host cell to activate a critical receptor for the bacterium, thereby promoting high-level bacterial attachment...
  75. ncbi Hormonal contraception and thrombotic risk: a multidisciplinary approach
    Cameron C Trenor
    Division of Hematology Oncology, Department of Medicine and Surgery, Children s Hospital Boston, Boston, Massachusetts 02115, USA
    Pediatrics 127:347-57. 2011
    ..Our multidisciplinary group has found that knowledge of the guidelines and individualized management plans have been particularly useful for informing discussions about hormonal and nonhormonal options across varied indications...
  76. ncbi The cleaved peptide of PAR1 is a more potent stimulant of platelet-endothelial cell adhesion than is thrombin
    R Brannon Claytor
    Department of Surgery, Division of Vascular Surgery, and Center for Platelet Function Studies, University of Massachusetts Medical School, Worcester, Mass 01655, USA
    J Vasc Surg 37:440-5. 2003
    ..We examined the effect of TR(1-41) on platelet activation and on platelet-endothelial cell adhesion...
  77. ncbi The cleaved peptide of the thrombin receptor is a strong platelet agonist
    M I Furman
    Center for Platelet Function Studies, University of Massachusetts Medical Center, Worcester, MA 01655, USA
    Proc Natl Acad Sci U S A 95:3082-7. 1998
    ..TR1-41-induced platelet activation was synergistic with TR42-55. In summary, the cleaved peptide of the seven-transmembrane domain TR (TR1-41) is a strong platelet agonist...
  78. ncbi Advances in antiplatelet therapy
    Alan D Michelson
    Center for Platelet Research Studies, Division of Hematology Oncology, Children s Hospital Boston, Dana Farber Cancer Institute, Harvard Medical School, Boston, MA 02115 5737, USA
    Hematology Am Soc Hematol Educ Program 2011:62-9. 2011
    ..Antagonists of the thrombin receptor protease-activated receptor 1 (PAR1) are also undergoing phase 3 trials, and many other novel antiplatelet agents are under investigation as antithrombotic agents...
  79. ncbi Two novel mutations in the alpha IIb calcium-binding domains identify hydrophobic regions essential for alpha IIbbeta 3 biogenesis
    W Beau Mitchell
    Department of Pediatrics, Mount Sinai School of Medicine, New York, NY 10029, USA
    Blood 101:2268-76. 2003
    ..These data suggest that the alphaIIb calcium-binding domains play a key structural role in the beta-propeller, and that the structural integrity of the calcium-binding domains is critical for integrin biogenesis...
  80. ncbi Clopidogrel linking evaluation of platelet response variability to mechanism of action
    Andrew L Frelinger
    J Am Coll Cardiol 46:646-7. 2005
  81. ncbi Aspirin resistance and its implications in clinical practice
    John Eikelboom
    McMaster University, Hamilton, Ontario, Canada
    MedGenMed 7:76. 2005
    ....
  82. ncbi Frequency of aspirin resistance in a community hospital
    Ahmadshah Mirkhel
    Department of Internal Medicine, Prince Georges Hospital Center, Cheverly, Maryland, USA
    Am J Cardiol 98:577-9. 2006
    ..Nonresponders to 81 mg/day frequently responded to 325 mg/day or to the addition of clopidogrel...
  83. ncbi Platelet activation and progression to complications
    Dean J Kereiakes
    Heart Center of Greater Cincinnati and Lindner Center at Christ Hospital, Cincinnati, Ohio, USA
    Rev Cardiovasc Med 7:75-81. 2006
    ..In general, optimal periprocedural outcomes require high levels of platelet inhibition. Combined administration of antiplatelet therapies may produce additive or synergistic inhibition of platelet-mediated thrombosis...
  84. ncbi Measuring antiplatelet drug effects in the laboratory
    Paul Harrison
    Oxford Haemophilia Centre and Thrombosis Unit, Churchill Hospital, Oxford, United Kingdom
    Thromb Res 120:323-36. 2007
    ..A clinically meaningful definition of "resistance" to antiplatelet drugs needs to be developed, based on data linking drug-dependent laboratory tests to clinical outcomes in patients...
  85. ncbi Antiplatelet therapy in children
    Sara J Israels
    Department of Pediatrics and Child Health, and the Manitoba Institute of Cell Biology, University of Manitoba, Winnipeg, Manitoba, Canada R3E 0V9
    Thromb Res 118:75-83. 2006
    ..Additional studies will be required to evaluate the relative benefits of aspirin and anticoagulants in these settings. A role for newer antiplatelet drugs in the management of pediatric arterial thrombosis is as yet unexplored...
  86. ncbi Antithrombotic therapy in neonates and children: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition)
    Paul Monagle
    Haematology Department, Royal Children s Hospital, Flemington Road, Parkville, Melbourne, Victoria 3052, Australia
    Chest 133:887S-968S. 2008
    ..For neonates with a first AIS, in the absence of a documented ongoing cardioembolic source, we recommend against anticoagulation or aspirin therapy (Grade 1B)...
  87. ncbi The Ultegra rapid platelet-function assay: comparison to standard platelet function assays in patients undergoing percutaneous coronary intervention with abciximab therapy
    Guy L Wheeler
    Wake Forest University School of Medicine, Winston-Salem, NC 27157-1045, USA
    Am Heart J 143:602-11. 2002
    ..Ultegra RPFA measurements are not operator-dependent and are not influenced by concomitant medications, hematologic parameters, or demographics...
  88. ncbi Neonatal platelet function
    Sara J Israels
    Department of Pediatrics and Child Health University of Manitoba, Winnipeg, Manitoba, Canada
    Semin Thromb Hemost 29:363-72. 2003
    ..In the immediate newborn period, this enhanced platelet adhesion may compensate for the decreased intrinsic platelet activation in healthy neonates, but may leave sick neonates at increased risk of bleeding...
  89. ncbi Platelet function monitoring in patients with coronary artery disease
    Paul A Gurbel
    Sinai Center for Thrombosis Research, Sinai Hospital of Baltimore, Baltimore, Maryland, USA
    J Am Coll Cardiol 50:1822-34. 2007
    ....
  90. ncbi Effects of physiologic agonists on canine whole blood flow cytometry assays of leukocyte-platelet aggregation and platelet activation
    Inge Tarnow
    Department of Basic Animal and Veterinary Sciences, Faculty of Life Sciences, University of Copenhagen, 7 Grønnegaardsvej, DK 1870 Frederiksberg C, Denmark
    Vet Immunol Immunopathol 123:345-52. 2008
    ..In conclusion, we have developed flow cytometry assays to measure LPAs and platelet activation in canine whole blood, and have explored the effect of various physiologic agonists at different concentrations...
  91. ncbi An additional mechanism of action of abciximab: dispersal of newly formed platelet aggregates
    Stanley J Marciniak
    Centocor, Malvern, PA 19355, USA
    Thromb Haemost 87:1020-5. 2002
    ..In vivo, abciximab may destabilize coronary thrombi by preventing aggregate formation and dispersing mural thrombi...
  92. ncbi Noncompliance in cardiovascular clinical trials
    Victor L Serebruany
    Heart Drug Research Laboratories, Towson, MD, USA
    Am Heart J 150:882-6. 2005
  93. ncbi Platelet-monocyte aggregates in patients with chronic venous insufficiency remain elevated following correction of reflux
    Michael J Rohrer
    Division of Vascular Surgery and the Center for Platelet Function Studies, The University of Massachusetts Medical School, 55 Lake Avenue, North Worcester 01655, USA
    Cardiovasc Surg 10:464-9. 2002
    ..The purpose of this study was to determine whether patients with CVI maintain elevated levels of PMAs following complete surgical correction of chronic venous insufficiency...
  94. ncbi Antithrombotic therapy in children: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy
    Paul Monagle
    Division of Laboratory Services, Royal Children s Hospital, Department of Paediatrics, University of Melbourne, Flemington Rd, Parkville, Melbourne, Vic, Australia 3052
    Chest 126:645S-687S. 2004
    ..v. gammaglobulin within 10 days of the onset of symptoms (Grade 1A)...
  95. ncbi Cystic fibrosis heterozygotes do not have increased platelet activation
    Inge Tarnow
    Department of Physiology and Biochemistry, University of Copenhagen, The Faculty of Life Sciences, Frederiksberg C, Denmark
    Thromb Res 121:159-62. 2007
    ..Platelet hyperreactivity in CF heterozygotes would be an important cardiovascular risk factor, since approximately 1 in 25 Caucasians is a CF carrier...